Revvity Stock
Revvity, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United States
- CEO
- Prahlad R. Singh
- Employees
- 11,000
- Market cap
- $17 B
- IPO
- 06/07/1965
Based in Waltham, Massachusetts, Revvity, Inc. operates in the Healthcare / Medical - Diagnostics & Research industry and has operated under this name since April 2023, following its previous identity as PerkinElmer, Inc. The U.S. corporation serves a wide spectrum of customers from the pharmaceutical, biotechnology,…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Revvity stock: price history
1D
-1.3%
1W
-1.0%
1M
+4.7%
6M
+62.5%
YTD
+57.8%
1Y
+62.4%
2Y
+27.0%
5Y
-10.1%
10Y
+190.8%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~45% stronger price swings than usual
Revvity stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
2 more assignments (Enabler/Second row) Pro-only.
Revvity, Inc. is a globally operating healthcare company that distributes its activities across Life Sciences and Diagnostics. The business encompasses the provision of cutting-edge instrumentation, software, reagents, and specialized services. In Discovery & Analytical Solutions, the company serves research facilities, the chemical industry, and the environmental and agricultural sectors with analytical technologies and laboratory services. The Diagnostics segment focuses on early detection of genetic abnormalities and infectious diseases through assay platforms and diagnostic instruments. The revenue structure comprises product sales, software subscriptions, and services, with a significant portion of the customer base consisting of pharmaceutical and biotechnology companies, research institutes, and public health authorities.
- Revenue model
- Mixed
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Low
Ask the agents about Revvity
Analyst assessment of Revvity
PRICE TARGET LOW
US$100.00
CONSENSUS
US$132.13
MEDIAN
US$130.00
PRICE TARGET HIGH
US$165.00
0
STRONG BUY
15
BUY
14
HOLD
0
SELL
0
STRONG SELL
29
TOTAL · Buy
As of: 13/10/2026
Revvity stock metrics
P/E
72.69
P/B
2.36
EV/EBITDA
25.23
RETURN ON EQUITY
0.7%
NET MARGIN
7.1%
DEBT/EQUITY
0.46
DIVIDEND YIELD
0.2%
AS OF
05/07/2026
Free float & liquidity
FREE FLOAT
91.9%
FLOAT SHARES
102,492,109
AVG. DAILY VOLUME (30D)
2,081,259
Insider transactions (SEC)
Gonzales Anita
Krakowiak Maxwell
Vohra Tajinder S
MICHAS ALEXIS P
Goldberg Joel S
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -1.3%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Revvity stock
What does Revvity do?
Revvity, Inc. is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United States.
The CEO is Prahlad R. Singh, the company employs around 11,000 people.
The IPO was on 06/07/1965; the stock trades on NYSE under the ticker RVTY.
What do analysts say about Revvity stock?
29 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$132.13, ranging from US$100.00 to US$165.00, with a median of US$130.00.
This is an external assessment, not a statement by Market Jury.
When does Revvity report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 45% stronger than usual.
Does Revvity pay a dividend?
Yes. The last dividend was US$0.07 per share, ex-date 23/10/2026, paid on 13/11/2026.
The dividend yield is 0.2% (as of 05/07/2026).
Which stocks are comparable to Revvity?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
How can I get Revvity stock analyzed?
Clicking "Analyze stock" lets five strategies assess Revvity against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.